You are here
Interview with Richard Gralla
Recorded at TAO (Transatlantic Oncology meeting), November 20-21, 2014, Paris
Richard Gralla gives an update on the developments regarding new MASCC / ESMO guidelines for the prevention of cancer treatment related nausea and vomiting. He anticipates a lot of significant and interesting changes in the guidelines. Gralla, who chaired a session on anti PD-1 and anti PD-L1 drugs, also explains the mode of action of this interesting new class of drugs, and sees potential in now having three major ways to attack cancer cells: chemotherapy, genetic mutations and rearrangements, and the new therapies using the immune checkpoint.
Richard Gralla, A. Einstein School of Medicine, NY